Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with .
Santhera Pharmaceuticals Holding AGMarch 3, 2021 GMT Pratteln, Switzerland, March 3, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD), conducted by partner ReveraGen Biopharma Inc. Subject to a positive 6-month topline data readout of this first study phase, this could allow for a regulatory submission to the US FDA in Q1-2022 with the potential to offer an alternative to current standard of care in DMD.
Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Grünenthal Germany is a Great Place to Work®
News provided by
Share this article
Great Place to Work
® and a
Great Start! company for apprentices. The company was awarded these two certifications based on the positive feedback that its employees shared during the
Great Place to Work
® survey in 2020 and a successfully completed external audit. We are pleased with this positive feedback from our employees particularly in times of the pandemic. It shows us that employees feel connected to the company – despite contact restrictions and working from home, says Oliver Lamm, Head HR Germany. At Grünenthal we actively create an attractive working environment based on our strong corporate culture.
Grünenthal Germany is a Great Place to Work® prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pratteln, Switzerland, February 24, 2021 - Santhera Pharmaceuticals